Every Form 4 that Treace Medical Concepts, Inc. (TMCI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TMCI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TMCI filings page.
TREACE MEDICAL CONCEPTS, INC. (TMCI) CEO and director John T. Treace reported open‑market purchases of a total of 55,944 shares of common stock on August 20, 21 and 24, 2026 at weighted average prices of $4.44, $4.35 and $4.34 per share, respectively. The filing also reports several large indirect common stock holdings held by his spouse and in various trusts, for which he disclaims beneficial ownership, and notes that his reported holdings include 542,784 restricted stock units. The Rule 10b5‑1 checkbox is not marked, indicating these purchases were not reported as made under a trading plan.
TREACE MEDICAL CONCEPTS, INC. reporting person Sean F. Scanlan, Chief Innovation Officer, reported a Form 4 transaction involving 9,814 shares of common stock delivered or withheld for payment of exercise price or tax liability. Following this disposition, he directly holds 679,863 shares of common stock, which includes 463,167 restricted stock units and reflects a transfer of 15,000 shares to a former spouse pursuant to a domestic relations order.
TREACE MEDICAL CONCEPTS, INC. reported that Chief Financial Officer Mark Hair had 37,102 shares of common stock withheld or delivered on August 9, 2026 to satisfy exercise price or tax liability. Following this code F disposition, he directly holds 914,900 shares of common stock, including 717,604 restricted stock units.
TREACE MEDICAL CONCEPTS, INC. reported that officer Scot Michael Elder, Chief Legal & Compliance Officer and Corporate Secretary, had 16,253 shares of common stock disposed of in a code F transaction, representing shares delivered or withheld for payment of an exercise price or tax liability. Following this transaction, Elder directly held 778,683 common shares, which the company notes include 590,697 restricted stock units.
Treace Medical Concepts Chief Executive Officer John T. Treace reported open-market share purchases and corrected an earlier reporting error. On June 10 he bought 14,715 shares of common stock at a weighted average price of $4.0240 per share, and on June 11 he bought 9,891 shares at a weighted average price of $4.0423 per share.
The amendment states the original Form 4 had misreported these purchases as 29,430 and 22,887 shares, respectively, and is being corrected for this administrative error. After these transactions, he directly holds 7,348,439 common shares, which includes 542,784 restricted stock units, and also reports indirect holdings through various trusts and his spouse, while disclaiming beneficial ownership of certain spouse- and trust-held shares.
TREACE MEDICAL CONCEPTS, INC. Chief Executive Officer John T. Treace reported open-market purchases of company common stock. He bought 29,430 shares on June 10 at a weighted average price of $4.024 per share and 22,887 shares on June 11 at a weighted average price of $4.0434, totaling 52,317 shares.
The filing notes these prices are weighted averages, with individual trades on June 10 ranging from $3.96 to $4.17 and on June 11 from $3.93 to $4.10. Following these purchases, he directly holds 7,376,150 common shares, including 542,784 restricted stock units. Several trusts and his spouse also hold additional shares indirectly associated with him, but he disclaims beneficial ownership of those holdings.
Treace Medical Concepts Chief Executive Officer John T. Treace purchased 50,000 shares of common stock in an open-market transaction on June 1, 2026 at a weighted average price of $3.5583 per share, with individual prices ranging from $3.51 to $3.60.
Following this purchase, he directly holds 7,323,833 shares of common stock, which includes 542,784 restricted stock units. He also reports additional indirect holdings through various trusts and his spouse, while expressly disclaiming beneficial ownership of those indirectly held shares.
Treace Medical Concepts CEO John T. Treace increased his stake by buying 115,520 shares of common stock in open-market transactions. The purchases occurred on May 26, 27, and 28, 2026 at weighted average prices of about $2.79, $2.87, and $3.02 per share, respectively. After these direct purchases, he held 7,273,833 common shares, which include 542,784 restricted stock units. He also reports additional indirect holdings through trusts and his spouse, while expressly disclaiming beneficial ownership of those indirectly held shares.
BAKEWELL JOHN K reported acquisition or exercise transactions in this Form 4 filing.
TREACE MEDICAL CONCEPTS director John K. Bakewell received an equity grant and updated his holdings. He was granted 30,000 restricted stock units, each convertible into one share of common stock, which will vest 100% on the earlier of May 19, 2027 or the 2027 annual stockholder meeting, subject to continued service. Bakewell elected to defer delivery of the shares until a change in control, his separation of service, or the fifth anniversary of the grant date. Following the grant, he holds 204,056 shares directly, including the 30,000 RSUs, and additional indirect holdings of 92,300 shares as trustee of a trust and 250,000 shares held by his spouse as trustee of a trust.
Kiernan Jane E reported acquisition or exercise transactions in this Form 4 filing.
Treace Medical Concepts director Jane E. Kiernan received a new equity award in the form of restricted stock units (RSUs). The Form 4 shows a grant of 30,000 RSUs with no cash paid per unit, bringing her direct holdings to 93,949 shares of common stock, including these RSUs.
The RSUs will be 100% vested on the earlier of May 19, 2027 or the date of the 2027 annual stockholder meeting, as long as she continues serving the company through that date. She has also elected to defer delivery of the underlying shares until the earlier of a change in control of the company or her separation of service, so the grant is a long-term, service-based compensation award rather than an immediate share issuance.
Berry Lance A reported acquisition or exercise transactions in this Form 4 filing.
Treace Medical Concepts director Lance A. Berry received an equity grant in the form of restricted stock units. He was awarded 30,000 RSUs tied to the company’s common stock, with each unit convertible into one share upon vesting. These RSUs will vest 100% on the earlier of May 19, 2027 or the 2027 annual meeting of stockholders, as long as he continues serving the company through that date. Berry has elected to defer delivery of the underlying shares until the earlier of a change in control or his separation of service. Following this grant, his direct holdings total 74,593 shares, including the 30,000 RSUs.
Jain Deepti reported acquisition or exercise transactions in this Form 4 filing.
Treace Medical Concepts director Deepti Jain reported receiving a grant of 30,000 restricted stock units (RSUs) of common stock at no purchase price. These RSUs will vest 100% on the earlier of May 19, 2027 or the 2027 annual meeting of stockholders, conditioned on continued service. Following this award, Jain holds 100,243 shares in total, including the 30,000 RSUs.
HAMILTON LAWRENCE W reported acquisition or exercise transactions in this Form 4 filing.
Treace Medical Concepts director Lawrence W. Hamilton reported a grant of 30,000 restricted stock units (RSUs) of Common Stock. The award was recorded at a price of $0.00 per share, reflecting a stock-based compensation grant rather than an open-market purchase.
The RSUs will be 100% vested on the earlier of May 19, 2027 or the 2027 annual meeting of stockholders, as long as Hamilton continues serving the company through that date. He has elected to defer receipt of the underlying shares until the earlier of a change in control or his separation of service. After this grant, his direct holdings total 74,056 shares, including 30,000 RSUs.
Treace Medical Concepts director Betsy Hanna received an equity award of 30,000 restricted stock units (RSUs). Each RSU converts into one share of common stock and will vest 100% on the earlier of May 19, 2027 or the 2027 annual stockholder meeting, contingent on continued service. After this grant, she holds 75,243 shares, including the 30,000 RSUs, with settlement of these units deferred until a change in control or her separation of service.
Treace Medical Concepts, Inc. Chief Executive Officer John T. Treace reported open-market purchases of the company’s common stock. On May 14, he bought 61,750 shares at a weighted average price of $2.6153 per share. On May 13, he bought 49,013 shares at $2.4592 per share, and on May 12, he bought 43,000 shares at $2.1739 per share, all in multiple transactions within stated price ranges. Following these purchases, he directly owns 7,158,313 shares, which include 542,784 restricted stock units, and also reports indirect holdings through trusts and his spouse while disclaiming beneficial ownership of those indirectly held shares.
Treace Medical Concepts, Inc. Chief Financial Officer Mark Hair reported a routine share disposition related to tax withholding. On this Form 4, 11,547 shares of common stock were withheld to cover tax obligations, leaving him with 952,002 shares, including 786,691 restricted stock units.
Treace Medical Concepts, Inc. Chief Financial Officer Mark Hair reported an equity compensation grant of 100,000 performance stock units. Each PSU entitles him to one share of common stock upon vesting, reflecting a non-cash, compensation-related acquisition rather than an open-market purchase.
The PSUs were earned after the Compensation Committee certified achievement of a performance goal and will vest 25% on April 15, 2026 and 25% on each February 15 of 2027, 2028 and 2029, subject to his continued service. Following this award, he directly holds 963,549 shares of common stock, which include 811,691 restricted stock units.
Treace Medical Concepts Chief Legal & Compliance Officer Scot Michael Elder reported routine tax-withholding dispositions of company stock. On two March dates, a total of 1,850 shares of common stock were delivered to cover tax obligations. Following these transactions, Elder directly held 794,936 common shares. Footnotes indicate these holdings include restricted stock units.
Treace Medical Concepts Chief Innovation Officer Sean F. Scanlan reported tax-withholding dispositions of company stock. On March 8 and March 10, 2026, a total of 1,797 shares of Common Stock were withheld to satisfy tax obligations, not sold on the open market.
After the March 10 transaction, he directly holds 704,677 shares of Common Stock, which includes 509,648 restricted stock units.
Treace Medical Concepts, Inc. director and Chief Executive Officer John T. Treace reported routine share withholding to cover tax obligations on equity awards. On two dates, a total of 7,083 shares of common stock were disposed of as tax-withholding transactions, not open-market sales. After these withholding events, he directly owns 7,004,550 common shares. Footnotes note that certain reported positions include 563,403 and 542,784 restricted stock units and that he disclaims beneficial ownership of shares held by his spouse and in various trusts where he or his spouse serve as trustee or co-trustee.
Treace Medical Concepts, Inc. Chief Financial Officer Mark Hair reported routine share dispositions tied to tax withholding on equity compensation. On March 8 and March 10, 2026, a total of 4,659 shares of common stock were withheld to satisfy tax liabilities, rather than sold on the open market.
After these transactions, Hair directly holds 863,549 shares of common stock, which includes 723,147 restricted stock units as of March 10, 2026. These entries reflect compensation-related mechanics, not discretionary buying or selling.
Treace Medical Concepts' Chief Innovation Officer, Sean F. Scanlan, exercised stock options and received common shares. On February 10, 2026, a stock option for 16,875 shares with a $1.05 exercise price was exercised, converting into 16,875 shares of common stock. Following this transaction, Scanlan directly beneficially owned 706,474 shares of common stock, which includes 511,291 restricted stock units.
Treace Medical Concepts, Inc. reported an equity award to its Chief Commercial Officer, Gaetano Guglielmino. On January 22, 2026, he was granted 150,000 restricted stock units (RSUs) of common stock at a price of $0 per share. Each RSU converts into one share of common stock as it vests. The RSUs vest in four equal annual installments, starting on January 22, 2027 and ending on January 22, 2030, conditioned on his continued service with the company. Following this grant, he beneficially owns 490,901 shares of common stock, including 422,250 RSUs.
Treace Medical Concepts Chief Legal & Compliance Officer Scot Michael Elder reported equity compensation and related share movements. On January 22, 2026, he disposed of 9,451 shares of Common Stock in a transaction coded "F" at a price of $0 per share, leaving him with 534,286 shares beneficially owned immediately after that line item. The same day, he acquired 262,500 shares of Common Stock in a transaction coded "A" at $0 per share, reported as restricted stock units.
The footnotes explain that these 262,500 RSUs each convert into one share of Common Stock upon vesting and vest in equal annual installments over four years, from January 22, 2027 through January 22, 2030, subject to continued service. After the reported transactions, Elder is shown as beneficially owning 796,786 shares, which includes 641,470 restricted stock units.
Treace Medical Concepts' Chief Financial Officer Mark Hair reported equity compensation activity in company stock. On January 22, 2026, he disposed of 17,037 shares of Common Stock at a stated price of $0, leaving him with 493,208 shares directly owned after that transaction, which included 351,134 restricted stock units.
On the same date, he was awarded 375,000 restricted stock units (RSUs) for which he is entitled to receive one share of Common Stock per RSU upon vesting at no cost. These RSUs vest in equal annual installments over four years, from January 22, 2027 through January 22, 2030, subject to his continued service. Following this grant, he directly beneficially owned 868,208 shares, which included 726,134 restricted stock units.
Treace Medical Concepts Chief Innovation Officer Sean F. Scanlan reported equity transactions in company stock. On January 21, 2026, he exercised a stock option for 53,500 shares of Common Stock at an exercise price of $0.72 per share, converting a previously held option into directly owned shares. On January 22, 2026, he received a grant of 262,500 restricted stock units (RSUs), each RSU representing one future share of Common Stock upon vesting. The RSUs vest in equal annual installments over four years from January 22, 2027 through January 22, 2030, contingent on his continued service with the company.
Treace Medical Concepts, Inc. Chief Executive Officer John T. Treace, who is also a director and 10% owner, reported equity award activity in company common stock on January 22, 2026.
One transaction disposed of 14,254 shares of common stock at $0 per share, and another transaction added 250,000 restricted stock units (RSUs) at $0 per share. After these transactions, he directly beneficially owned 7,011,633 shares of common stock, which, according to the footnotes, include 571,871 RSUs.
The 250,000 RSUs vest in equal annual installments over four years, with vesting dates on January 22, 2027 through January 22, 2030, contingent on his continued service. Additional shares are held by his spouse and in related trusts, and he disclaims beneficial ownership of those holdings.
Treace Medical Concepts, Inc. Chief Financial Officer reports an insider stock transaction. On 01/10/2026, Mark Hair reported an "F" code transaction involving 8,719 shares of common stock at a reported price of $0 per share. Following this transaction, he beneficially owned 510,245 shares of Treace Medical Concepts common stock in direct form. A noted portion of this position consists of 398,009 restricted stock units, which typically represent share-based awards that may settle in stock over time.
Treace Medical Concepts, Inc. officer Elder Scot Michael, Chief Legal & Compliance Officer and Corporate Secretary, reported a transaction in company common stock dated 01/10/2026. A transaction coded "F" involved 4,544 shares at a reported price of $0 per share, after which he beneficially owned 543,737 common shares. This beneficial ownership figure includes 410,845 restricted stock units.
Treace Medical Concepts, Inc. reported an insider ownership update for Chief Executive Officer and director John T. Treace. On January 10, 2026, a Form 4 lists a transaction in which 13,219 shares of common stock were disposed of at a price of $0.00 per share under transaction code F, leaving 6,775,887 common shares directly beneficially owned. This direct position includes 363,867 restricted stock units.
The filing also reports additional indirect holdings of common stock attributed to Mr. Treace’s spouse and various trusts, with share amounts of 1,605,000, 1,471,250, 1,839,063, and 408,816. The reporting person disclaims beneficial ownership of shares held by his wife directly or in trusts she controls, as well as shares held in trusts for which he serves as trustee or co‑trustee.
Treace Medical Concepts (TMCI) reported an insider transaction on a Form 4. On 10/24/2025, the Chief Innovation Officer recorded a transaction in Common Stock with code F for 208 shares at $0, marked as a disposition. Following the transaction, the officer beneficially owns 373,599 shares, which includes 283,948 restricted stock units. Ownership is reported as direct.
Treace Medical Concepts (TMCI) reported an insider Form 4 for its Chief Legal & Compliance Officer and Corporate Secretary. On 10/25/2025, the filer disposed of 984 shares of common stock at $0 under transaction code F. Following the transaction, the filer beneficially owned 548,281 shares directly. A footnote states this figure includes 426,170 restricted stock units.